Pregnant type 1 diabetes women with rises in C-peptide display higher levels of regulatory T cells: A pilot study.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
05 2021
Historique:
received: 24 03 2020
revised: 21 04 2020
accepted: 22 04 2020
pubmed: 7 9 2020
medline: 27 1 2022
entrez: 6 9 2020
Statut: ppublish

Résumé

During pregnancy of type 1 diabetes (T1D) women, a C peptide rise has been described, which mechanism is unclear. In T1D, a defect of regulatory T cells (Tregs) and its major controlling cytokine, interleukin-2 (IL2), is observed. Evolution of clinical, immunological (Treg (CD4+CD25hiCD127-/loFoxp3+ measured by flow cytometry and IL2 measured by luminex xMAP technology) and diabetes parameters (insulin dose per day, HbA1C, glycaemia, C peptide) was evaluated in 13 T1D women during the three trimesters of pregnancy and post-partum (PP, within 6 months) in a monocentric pilot study. Immunological parameters were compared with those of a healthy pregnant cohort (QuTe). An improvement of beta cell function (C peptide rise and/or a decrease of insulin dose-adjusted A1c index that estimate individual exogenous insulin need) was observed in seven women (group 1) whereas the six others (group 2) did not display any positive response to pregnancy. A higher level of Tregs and IL2 was observed in group 1 compared to group 2 during pregnancy and at PP for Tregs level. However, compared to the healthy cohort, T1D women displayed a Treg deficiency CONCLUSION: This pilot study highlights that higher level of Tregs and IL2 seem to allow improvement of endogenous insulin secretion of T1D women during pregnancy.

Identifiants

pubmed: 32891755
pii: S1262-3636(20)30121-X
doi: 10.1016/j.diabet.2020.04.005
pii:
doi:

Substances chimiques

C-Peptide 0
Interleukin-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101188

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

C Amouyal (C)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France; Sorbonne Université, Nutrition and Obesities: Systemic Approaches (NutriOmics) Research Unit, UMRS U1269, Paris, France. Electronic address: chloe.amouyal@aphp.fr.

D Klatzmann (D)

AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (I2B), Sorbonne Université, Paris, France; Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.

E Tibi (E)

AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (I2B), Sorbonne Université, Paris, France.

J-E Salem (JE)

Clinical Investigation Centre Paris-Est, CIC-1421, UNICO-GRECO Cardio-oncology Program, INSERM, Department of Pharmacology, Sorbonne Université, Paris, France; Department of Medicine and Pharmacology, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA.

M Halbron (M)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France.

M Popelier (M)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France.

S Jacqueminet (S)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France.

C Ciangura (C)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France.

O Bourron (O)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France; Sorbonne Université, INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Institute of Cardiometabolism and Nutrition, Paris, France.

F Andreelli (F)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France; Sorbonne Université, Nutrition and Obesities: Systemic Approaches (NutriOmics) Research Unit, UMRS U1269, Paris, France.

A Hartemann (A)

AP-HP, Pitié-Salpêtrière Hospital, Diabetology Department, F-75013 Paris, France; Sorbonne Université, INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Institute of Cardiometabolism and Nutrition, Paris, France.

M Rosenzwajg (M)

AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (I2B), Sorbonne Université, Paris, France; Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH